Elevated Serum CD44 Level Is Associated With Unfavorable Outcome in Non-Hodgkin's Lymphoma by Raija Ristamäki, Heikki Joensuu, Kimmo Lappalainen, Lasse.

Slides:



Advertisements
Similar presentations
Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):
Advertisements

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
Investigating a New Methodology for the Detection of Low Frequency 17p Deleted Clones in Chronic Lymphocytic Leukaemia (CLL): Impact on Prognostic Outcome.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,
FDG-PET/CT Metabolic Tumor Volume: A New Prognostic Marker in Hodgkin Lymphoma? by Marine Boulesteix, Mohamed Touati, Julie Abraham, Sandrine Verbeke,
The influence of high-altitude living on body iron
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells by Changchun.
Do HSCs divide asymmetrically?
Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.
EBV DNA: a Hodgkin lymphoma biomarker?
Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.
Adaptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells Enhances Lymphocyte Recovery after Cyclophosphamide - Fludarabine.
by James O. Armitage, and Dan L. Longo
Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Expression of CD10 by Human T Cells That Undergo Apoptosis Both In Vitro and In Vivo by Giovanna Cutrona, Nicolò Leanza, Massimo Ulivi, Giovanni Melioli,
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Tax fingerprint in adult T-cell leukemia
The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.
Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,
Nonmyeloablative conditioning for relapsed follicular lymphoma
Superior Survival after Autologous vs
Mechanisms of HIV-associated lymphocyte apoptosis
T regulatory cells turn on T regulatory cells
by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu
Fusion genes in cord blood
An Unusual Cause of Abdominal Pain in Sickle Cell Disease
Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.
Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,
AIDS-Related Extranodal Non-Hodgkin's Lymphomas With Plasma Cell Differentiation by Antonino Carbone, Annunziata Gloghini, Vincenzo Canzonieri, Umberto.
Blood Volume 92(10): November 15, 1998
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index by Chor-Sang Chim, Shing-Yan.
Lymphoma spread? Target CD47-SIRPα!
How I treat refractory CLL
by George Z. Rassidakis, Mauricio P. Oyarzo, and L. Jeffrey Medeiros
Anergy: the CLL cell limbo
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.
Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,
Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma  Tanya M. Wildes, Kristan M. Augustin, Diane.
Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma  Ivan Aksentijevich,
How I treat Burkitt lymphoma in adults
Anti-CD20-IL-21 fusokine: the tail wags the dog
CR-rate ratios with 95% CIs
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium.
Full Uncapped Doses Of Chemotherapy In Non-Hodgkin's Lymphoma Patients With a High Body Surface Area Are Well Tolerated With No Increase In Toxicity, and.
by Lapo Alinari, and Kristie A. Blum
by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal
Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.
Is Skull-Base to Proximal Thigh PET/CT Enough
Two major molecular subgroups within PTCL-NOS with biological and overall survival differences. Two major molecular subgroups within PTCL-NOS with biological.
CD47 functions as a molecular switch for erythrocyte phagocytosis
Outcomes in patients with PTCL
Presentation transcript:

Elevated Serum CD44 Level Is Associated With Unfavorable Outcome in Non-Hodgkin's Lymphoma by Raija Ristamäki, Heikki Joensuu, Kimmo Lappalainen, Lasse Teerenhovi, and Sirpa Jalkanen Blood Volume 90(10):4039-4045 November 15, 1997 ©1997 by American Society of Hematology

The epitope mapping. The epitope mapping. MoAb 1F1 recognizes CD44 transfected cells after incubation with MoAb Hermes-3. Combination of Hermes-3–biotinylated Hermes-3 is used as the negative control. b, biotinylated. Raija Ristamäki et al. Blood 1997;90:4039-4045 ©1997 by American Society of Hematology

The prognostic influence of s-CD44 in all lymphomas and separately in the subgroups of DLCL and low-grade lymphomas. The prognostic influence of s-CD44 in all lymphomas and separately in the subgroups of DLCL and low-grade lymphomas. Raija Ristamäki et al. Blood 1997;90:4039-4045 ©1997 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.